Description

PA007279.m2a: Recombinant Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7) , Mouse IgG2a Kappa

The in vivo grade recombinant anti-mouse TIGIT monoclonal antibody, Mouse IgG2a Kappa (clone: 10A7) was produced in mammalian cells.

Background of Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7)

The 10A7 antibody binds to the TIGIT protein (WUCAM, Vstm3 or VSIG9), a novel immune checkpoint receptor with inhibitory function. TIGIT is expressed on T cells and natural killer (NK) cells, and several human cancers, including melanoma, NSCLC, and colorectal cancer. Similar to PD-1, the TIGIT receptor limits antitumor immune response in cancer.

References for Anti-mouse TIGIT Antibody(10A7):

1、TIGIT limits immune pathology during viral infections
Schorer, M., et al. Nat Commun. 2020 Mar;11(1):1288. doi: 10.1038/s41467-020-15025-1. PMID: 32152316
“TIGIT (T cell immunoglobulin and ITIM domain) is a co-inhibitory receptor that acts as an important immune checkpoint, as it limits both T cell-driven inflammation and T cell and NK cell-dependent anti-tumor immunity. …TIGIT is known to exert its immune suppressive function through various modes of action, including direct and indirect inhibition of T cells. …TIGIT blockade or deficiency has been shown to lead to the breakdown of peripheral tolerance in HBsAg-tg mice, resulting in the development of hepatitis and fibrosis. …As TIGIT ligation is functionally linked to IL-10 expression that is known to both promote virus persistence in vivo, but also limit adverse immunopathological damage, the TIGIT pathway might represent an important regulatory gatekeeper for the control of viral infections. …To further investigate this link between TIGIT and IL-10 expression in vivo, we chronically infected Thy1.1-IL-10 reporter with LCMV clone 13 and again treated them with blocking anti-TIGIT antibody (1B4) or isotype control.”

2、Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
Dixon, K. O., et al. J Immunol. 2018 Apr;200(8):3000-3007. doi: 10.4049/jimmunol.1700407. PMID: 29500245
“Coinhibitory receptors, such as CTLA-4 and PD-1, play a critical role in maintaining immune homeostasis by dampening T cell responses. …The novel coinhibitory receptor TIGIT (T cell Ig and ITIM domain) has been shown to play an important role in modulating immune responses in the context of autoimmunity and cancer. …However, the molecular mechanisms by which TIGIT modulates immune responses are still insufficiently understood. …We have identified agonistic as well as blocking anti-TIGIT Ab clones that are capable of modulating T cell responses in vivo. …The Abs presented in this study can thus serve as important tools for detailed analysis of TIGIT function in different disease settings and the knowledge gained will provide valuable insight for the development of novel therapeutic approaches targeting TIGIT.”

3、The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Chan, C. J., et al. Nat Immunol. 2014 May;15(5):431-8. doi: 10.1038/ni.2850. PMID: 24658051
“CD96, CD226 (DNAM-1) and TIGIT belong to an emerging family of receptors that interact with nectin and nectin-like proteins. …CD226 activates natural killer (NK) cell–mediated cytotoxicity, whereas TIGIT reportedly counterbalances CD226. …In contrast, the role of CD96, which shares the ligand CD155 with CD226 and TIGIT, has remained unclear. …As a result, Cd96−/− mice displayed hyperinflammatory responses to the bacterial product lipopolysaccharide (LPS) and resistance to carcinogenesis and experimental lung metastases. …Our data provide the first description, to our knowledge, of the ability of CD96 to negatively control cytokine responses by NK cells. Blocking CD96 may have applications in pathologies in which NK cells are important.”

4、Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy
Burton, B. R., et al. Nat Commun. 2014 Sep 3;5:4741. doi: 10.1038/ncomms5741. PMID: 25182274
“By immunolabelling cells from Tg4Il10/GFP reporter mice, we could demonstrate a positive correlation between IL-10 production and the expression of LAG-3, TIGIT, PD-1 and TIM-3. However, expression of these markers was not uniquely restricted to the IL10+ population; only 11% of LAG-3+ cells were IL-10+ and ~50% of Tim-3+ or TIGIT+ cells were IL-10+. …CD49b was also found to correlate with IL-10 expression in CD4+ T cells from EDI-treated mice; however, within the LAG-3+CD49b+ population, only 33% of cells were found to express IL-10. …The controlled induction of cells secreting IL-10 is clearly a goal for effective immunotherapy of such hypersensitivity conditions. …By better understanding these processes, we will be able to refine and enhance therapeutic tolerance induction, minimizing treatment-associated risks, and achieving sustained modulation of pathogenic antigen-specific CD4+ T-cell activity. …Antigen-specific immunotherapy combats autoimmunity or allergy by reinstating immunological tolerance to target antigens without compromising immune function.”

5、Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development
Foks, A. C., et al. PLoS One. 2013 Dec 20;8(12):e83134. doi: 10.1371/journal.pone.0083134. PMID: 24376654
“TIGIT was upregulated on CD4+ T cells isolated from mice fed a Western-type diet in comparison with mice fed a chow diet. …A new-emerging complex network of costimulatory and coinhibitory molecules is formed by T cell immunoreceptor with Ig and ITIM domains (TIGIT, Vstm3, WUCAM), CD226 (DNAM-1), CD112 (PVRL2, nectin-2), and the poliovirus receptor (PVR, CD155). …Interference in this pathway by using TIGIT deficient mice has been shown to aggravate EAE through elevated secretion of proinflammatory cytokines such as IL-6, IFN-γ and IL-17, and by increased T cell proliferation. …During the experiments, mice were weighed and blood samples were obtained by tail vein bleeding. …In a separate in vitro experiment, DCs were co-cultured with CD4+ T cells in a 1∶4 ratio and increasing concentrations of agonistic anti-TIGIT.”

6、Cutting edge: TIGIT has T cell-intrinsic inhibitory functions
Joller, N., et al. J Immunol. 2011 Feb 1;186(3):1338-42. doi: 10.4049/jimmunol.1003081. PMID: 21199897
“Costimulatory molecules regulate the functional outcome of T cell activation, and disturbance of the balance between activating and inhibitory signals results in increased susceptibility to infection or the induction of autoimmunity. …Similar to the well-characterized CD28/CTLA-4 costimulatory pathway, a newly emerging pathway consisting of CD226 and T cell Ig and ITIM domain (TIGIT) has been associated with susceptibility to multiple autoimmune diseases. …In this study, we examined the role of the putative coinhibitory molecule TIGIT and show that loss of TIGIT in mice results in hyperproliferative T cell responses and increased susceptibility to autoimmunity. …TIGIT is thought to indirectly inhibit T cell responses by the induction of tolerogenic dendritic cells. By generating an agonistic anti-TIGIT Ab, we demonstrate that TIGIT can inhibit T cell responses directly independent of APCs. …Microarray analysis of T cells stimulated with agonistic anti-TIGIT Ab revealed that TIGIT can act directly on T cells by attenuating TCR-driven activation signals.”

Related Recombinant IgG Reference Antibodies:

recombinant mouse IgG2a isotype control antibody, In vivo grade

Syd Labs provides the following recombinant anti-mouse TIGIT monoclonal antibodies:

recombinant anti-mouse TIGIT antibodies (clone 1F4), In vivo grade

Anti-mouse TIGIT Antibody (10A7) from: Recombinant Anti-mouse TIGIT Monoclonal Antibody, Mouse IgG2a Kappa (Clone: 10A7): PA007279.m2a Syd Labs